Novopyxis
Raja Srinivas has an extensive work experience. Raja founded the company Asimov in 2017 and currently holds the position of Founder. Prior to this, they were the Co-founder and Advisor at Novopyxis, starting from 2013. Raja also has experience in research, having worked as a PhD Researcher at the Massachusetts Institute of Technology (MIT) from 2011 to 2016. Before that, they worked as an Undergraduate Research Assistant and Design Team Leader at The Johns Hopkins University from 2008 to 2011. Raja also served as an Undergraduate Research Fellow at the National Cancer Institute (NCI) in 2009. Raja began their career as a Research Assistant at the University at Buffalo (UB) from 2005 to 2007.
Raja Srinivas began their education at High Technology High School from 2003 to 2007, where they completed their high school education. Following this, they attended The Johns Hopkins University from 2007 to 2011, earning a Bachelor's Degree in Biomedical/Medical Engineering, Applied Mathematics And Statistics. Subsequently, they pursued further studies at the Massachusetts Institute of Technology, where they obtained a PhD in Bioengineering from 2011 to 2016.
This person is not in the org chart
This person is not in any teams
Novopyxis
Novopyxis is an award-winning biotechnology company dedicated to the development of therapeutics and medical devices. Novopyxis’ flagship drug was developed using in-house proprietary mathematical algorithms and has been validated across several different in vitro, ex vivo, and in vivo models. It activates a key anti-inflammatory receptor calledthe AT2R and is both cardioprotective and neuroprotective. Their therapeutic was recently awarded an orphan designation for "Pediatric Cardiomyopathy" from the FDA. Droplette was recently spun out from Novopyxis (www.droplette.io) and is focused on the development of a patented medical device for the delivery of large molecules, DNA/RNA, and proteins deep through skin, tissue, and cells. They are currently partnered with Leo Pharma for the development of their device for medical dermatology applications and have won several awards including the 2015 Graduate of MassCONNECT program via MassBio, 2015 Amgen Golden Ticket Winner, 2014 Mass Challenge Finalist, Winner of 2014 CASIS-Boeing Prize for Technology in Space, and Second place winner in 2015 M2D2 New Ventures Competition